Sanofi’s Icaria combo extends progression-free survival in multiple myeloma at Phase 3

pharmafile | February 6, 2019 | News story | Research and Development Icaria, Sanofi, multiple myeloma, pharma 

Sanofi has continued to make progress in the development of Icaria (isatuximab), with the company announcing that the therapy met its primary endpoint in combination with pomalidomide and low-dose dexamethasone in the treatment of relapsed/refractory multiple myeloma compared to the standard care.

A Phase 3 study for the treatment incorporated 307 participants across 96 centres in 24 countries who had previously received two or more anti-myeloma therapies, including at least two consecutive cycles of lenalidomide and a proteasome inhibitor given alone or in combination, confirmed that the combo succeeded in prolonging progression-free survival.

Further details were not given, but Sanofi revealed that full data form the study would be presented at an upcoming medical meeting, with regulatory submissions to come later in the year.  

The second most common type of haematologic cancer, multiple myeloma affects around 17,500 in the UK, with approximately 5,500 new diagnoses each year.

“There is a continuing need for new therapeutic options for multiple myeloma in patients who have either relapsed or are no longer responding to their current treatment,” explained Professor Kwee Yong, UK Icaria Trial Investigator and Professor of Haematology at University College London Hospital. “The ICARIA study confirms that the investigational agent, isatuximab, in combination with the current standard of care, pomalidomide, improves outcomes for these patients and I’m excited about how these data demonstrate the ability of this investigational compound to extend disease free life in patients living with relapsed/refractory multiple myeloma.”

Dr Marc Moodley, Medical Director for Sanofi Genzyme, added: “There is an unmet need in the management of relapsed/refractory multiple myeloma and the Icaria data represents a significant milestone for Sanofi Genzyme and our oncology portfolio. The isatuximab development programme continues to progress and we are committed to bringing this investigational compound forward as a potential new therapeutic option for patients as soon as possible.”

Matt Fellows

Related Content

Sanofi announce positive phase 2 data for MS drug frexalimab

French pharmaceutical and healthcare company Sanofi have announced positive trial data from its phase 2 …

Maze Therapeutics and Sanofi sign exclusive worldwide license agreement for Pompe disease treatment

Maze Therapeutics and Sanofi have announced that they have signed an exclusive worldwide license agreement …

Sanofi complete acquisition of mRNA company Translate Bio

French pharma giants Sanofi continues its run of acquisitions in 2021 by completing the deal …

Latest content